Skip to main content
SpringerLink
Log in

Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Abundant evidence from large-scale clinical trials supports the importance of lowering low-density lipoprotein cholesterol (LDL-C) to decrease the risk of cardiovascular disease (CVD) events. The LDL-C targets in various guidelines remain important treatment goals but, even in trials where statin therapy achieves substantial reduction of LDL-C, a significant number of CVD events still occur and the residual risk remains high. These findings suggest that lipid parameters other than LDL-C, such as high-density lipoprotein cholesterol (HDL-C), triglycerides, and LDL particle size, can influence the risk of CVD. On this basis, other strategies that can alter the lipid profile, in particular raising HDL.C, may provide additional benefits. Other factors such as HDL-C functionality and susceptibility to oxidation and inflammatory factors can also influence cardiovascular risk. In addition to the modifications of the lipid profile, statins have cholesterolindependent beneficial pleiotropic effects. The contribution of these effects to event reduction is not yet fully understood. Recently, the body of evidence has expanded to support the use of intensive statin therapy in broader patient populations. The JUPITER trial has shown the benefit of intensive statin treatment in low-risk subjects with high levels of high-sensitivity C-reactive protein and average levels of LDL-C. Unlike the setting of primary and secondary prevention, the results of statin trials in patients with heart failure have shown no clear benefit in terms of survival. The recently published AURORA trial was carried out to investigate the effect of rosuvastatin in patients with end-stage renal disease undergoing chronic hemodialysis. In this trial no benefit on cardiovascular events was shown with statin therapy. In conclusion, large outcomes trials have clearly shown that statin treatments have a favorable benefit/risk profile in a large range of patients at different levels of risk, with the exception of patients with heart failure and those with renal disease undergoing dialysis. Further evidence is needed on the role of therapeutic strategies on the so-called residual risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291:2616–2622.

    Article  PubMed  CAS  Google Scholar 

  2. Cardiovascular diseases. Fact sheet no. 317. February 2007. World Health Organization web site. Available at: www.who.int. Accessed April 2009.

  3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239.

    Article  PubMed  Google Scholar 

  4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.

    Google Scholar 

  5. Lipid Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. N Engl J Med. 1998;339:1349–1357.

    Article  Google Scholar 

  6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol loweringwith simvastatin in 20536 high-risk individuals: a randomized placebo controlled trial. Lancet. 2002;360:7–22.

    Article  Google Scholar 

  7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  8. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  9. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1317.

    Article  PubMed  CAS  Google Scholar 

  10. Baigent C, Keech A, Kearney PM,et al. Cholesterol Treatment Trialist’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.

    Article  PubMed  CAS  Google Scholar 

  11. Cannon CP, Steimberg BA, Murphy SA, et al. Metaanalysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–445.

    Article  PubMed  CAS  Google Scholar 

  12. LaRosa JC, Grundy SM, Waters DD,et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435.

    Article  PubMed  CAS  Google Scholar 

  13. De Lemos JA, Blazing MA, Wiviott SD, et al. A to Z Investigators. Early intensive vs a delayed conservative simvastin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–1316.

    Article  PubMed  Google Scholar 

  14. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction-22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med. 2004;350:1495–1504.

    Article  PubMed  CAS  Google Scholar 

  15. Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study group. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445.

    Article  PubMed  CAS  Google Scholar 

  16. Graham I, Atar D, Borch-Johnsen K,et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(suppl. 2):E1–E40.

    Article  PubMed  Google Scholar 

  17. Rosensen R. Statins: can the new generation make an impression? Expert Opin Emerg Drugs. 2004;9:269–279.

    Article  Google Scholar 

  18. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225–1228.

    Article  PubMed  Google Scholar 

  19. Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005;96:3K–13K.

    Article  PubMed  CAS  Google Scholar 

  20. Sacks FM, Rouleau JL, Moye LA,et al. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol. 1995;75:621–623.

    Article  PubMed  CAS  Google Scholar 

  21. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–1630.

    Article  PubMed  CAS  Google Scholar 

  22. Kelley GA, Kelley KS, Tran ZV. Aerobic exercise and lipids and lipoproteins in women: a meta-analysis of randomized controlled trial. J Womens Health. 2004;13:1148–1164.

    Article  Google Scholar 

  23. Kelley GA, Kelley KS. Aerobic exercise and lipids and lipoproteins in men: a meta-analysis of randomized controlled trial. J Mens Health Gend. 2006;3:61–70.

    Article  PubMed  Google Scholar 

  24. Yusuf S, Hawkan S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART Study): a case-control study. Lancet. 2004;364:937–952.

    Article  PubMed  Google Scholar 

  25. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am. 2008;37:663–684,ix.

    Article  PubMed  CAS  Google Scholar 

  26. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968–976.

    Article  PubMed  CAS  Google Scholar 

  27. Scaglione R, Argano C, Di Chiara T, Licata G. Obesity and cardiovascular risk: the new public health problem of worldwide proportions. Expert Rev Cardiovasc Ther. 2004;2:203–212.

    Article  PubMed  Google Scholar 

  28. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999;340:115–126.

    Article  PubMed  CAS  Google Scholar 

  29. Pearson TA, Mensach GA, Alexander RW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Center for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.

    Article  PubMed  Google Scholar 

  30. Ridker PM. High-sensitivity C reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813–1818.

    PubMed  CAS  Google Scholar 

  31. Ridker PM, Rifai N, Rose L, et al. Comparison of C reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565.

    Article  PubMed  CAS  Google Scholar 

  32. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599–2610.

    Article  PubMed  CAS  Google Scholar 

  33. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol. 2007;16:14–21.

    Article  PubMed  Google Scholar 

  34. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein: adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011.

    PubMed  CAS  Google Scholar 

  35. Ridker PM. C reactive protein and the prediction of cardiovascular events among those at intermediate risk moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129–2138.

    Article  PubMed  CAS  Google Scholar 

  36. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction (PROVE-IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28.

    Article  PubMed  CAS  Google Scholar 

  37. Field KM. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. Pharmacotherapy. 2005;25:1365–1377.

    Article  PubMed  CAS  Google Scholar 

  38. Sakkinen P, Abbott RD, Curb JD, et al. C-reactive protein and myocardial infarction. J Clin Epidemiol. 2002;55:445–451.

    Article  PubMed  Google Scholar 

  39. Ray KK, Cannon CP. The potential relevance of the multiple lipid independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46:1425–1433.

    Article  PubMed  CAS  Google Scholar 

  40. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–1965.

    Article  PubMed  CAS  Google Scholar 

  41. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114:281–288.

    Article  PubMed  CAS  Google Scholar 

  42. Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/dl: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45:1644–1648.

    Article  PubMed  CAS  Google Scholar 

  43. Gordon DJ, Rifklnd BM. High density lipoprotein — the clinical implications of recent studies. N Engl J Med. 1989;321:1311–1316.

    PubMed  CAS  Google Scholar 

  44. Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004;109(suppl. 1):iii8–iii14.

    Google Scholar 

  45. Castell WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA. 1986;256:2835–2838.

    Article  Google Scholar 

  46. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high density lipoprotein and its apolipoproteins: an idea whose time for testing is coming part I. Circulation. 2001;104:2376–2383.

    Article  PubMed  CAS  Google Scholar 

  47. Badimon J, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234–1241.

    Article  PubMed  CAS  Google Scholar 

  48. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med. 2007;357:1301–1310.

    Article  PubMed  CAS  Google Scholar 

  49. Linsel Nitsche P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4:193–205.

    Article  Google Scholar 

  50. Chapman MJ. Therapeutic elevation of HDLcholesterol to prevent atherosclerosis and coronary artery disease. Pharmacol Ther. 2006;11:893–908.

    Article  Google Scholar 

  51. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med. 2007;357:1301–1310.

    Article  PubMed  CAS  Google Scholar 

  52. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoproteins as a therapeutic target: a systematic review. JAMA. 2007;298:786–798.

    Article  PubMed  CAS  Google Scholar 

  53. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94:706–714.

    Article  PubMed  CAS  Google Scholar 

  54. Nissen S, Tardiff JC, Nicholls S, et al. Effect of the torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–1316.

    Article  PubMed  CAS  Google Scholar 

  55. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–1630.

    Article  PubMed  CAS  Google Scholar 

  56. Bots ML, Visseren FL, Evans GW, et al. RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2 Study): a randomized double-blind trial. Lancet. 2007;370:153–160.

    Article  PubMed  CAS  Google Scholar 

  57. Barter PJ, Caulfield M, Eriksson M, et al. ILLUMINATE Investigators. Effects of Torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122.

    Article  PubMed  CAS  Google Scholar 

  58. Ansell BJ, Watson KE, Fogelman AM, et al. High density lipoprotein function recent advances. J Am Coll Cardiol. 2005;46:1792–1798.

    Article  PubMed  CAS  Google Scholar 

  59. Ansell BJ, Fonarow GC, Fogelman AM. High density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep. 2006;8:405–411.

    Article  PubMed  CAS  Google Scholar 

  60. Nicholls SJ. HDL: still a target for new therapies? Curr Opin Investig Drugs. 2008;9:950–956.

    PubMed  CAS  Google Scholar 

  61. Jones P, Davidson MH, Stein EA, et al. STELLAR study group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152–160.

    Article  PubMed  CAS  Google Scholar 

  62. Schuster H, Barter PJ, Stender S, et al. Effective Reductions In Cholesterol Using Rosuvastatin Therapy I study group. Effect of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J. 2004;147:705–713.

    Article  PubMed  CAS  Google Scholar 

  63. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592.

    Article  PubMed  CAS  Google Scholar 

  64. Chapman MJ. Are the effect of statins on HDL cholesterol clinically relevant? Eur Heart J Suppl. 2004;6(suppl. C):c58–c63.

    Article  CAS  Google Scholar 

  65. Nicholls SJ. Rosuvastatin and progression of atherosclerosis. Expert Rev Cardiovasc Ther. 2008;6:925–933.

    Article  PubMed  CAS  Google Scholar 

  66. Bots ML. Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr Med Res Opin. 2006;22:2181–2190.

    Article  PubMed  Google Scholar 

  67. Davidson MH, Dembowski E. Atherosclerosis surrogate imaging trials come of age: for better or for worse? Curr Cardiol Rep. 2008;10:521–525.

    Article  PubMed  Google Scholar 

  68. Nash DT. Use of vascular ultrasound in clinical trials to evaluate new cardiovascular therapies. J Natl Med Assoc. 2008;100:222–229.

    PubMed  Google Scholar 

  69. Kastelein JJP, de Groot E. Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J. 2008;29:849–858.

    Article  PubMed  Google Scholar 

  70. Ballantyne CM. Clinical trial endpoints: angiograms, events and plaque instability. Am J Cardiol. 1998;82:5M–11M.

    Article  PubMed  CAS  Google Scholar 

  71. Tardif J-C, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 2006;113:2936–2942.

    Article  PubMed  Google Scholar 

  72. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA. 2004;291:1071–1080.

    Article  PubMed  CAS  Google Scholar 

  73. Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565.

    Article  PubMed  CAS  Google Scholar 

  74. Ballantyne CM, Raichlen JS, Nicholls JS. ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117:2458–2466.

    Article  PubMed  CAS  Google Scholar 

  75. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, highdensity lipoprotein cholesterol and regression of coronary atherosclerosis. JAMA. 2007;297:499–508.

    Article  PubMed  CAS  Google Scholar 

  76. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902–2009.

    Article  PubMed  CAS  Google Scholar 

  77. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on Atherosclerosis Progression in Familial Hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577–581.

    Article  PubMed  CAS  Google Scholar 

  78. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:2055–2060.

    Article  PubMed  CAS  Google Scholar 

  79. Crouse JR, Raichlen JS, Riley WA, et al. METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low risk individuals with subclinical atherosclerosis. JAMA. 2007;297:1344–1353.

    Article  PubMed  CAS  Google Scholar 

  80. Nicholls SJ, Raichlen JS, Ballantyne CM, et al. Intravascular ultrasound evaluation of the effect of rosuvastatin versus atorvastatin on progression of coronary atherosclerosis: design of the SATURN study. Atheroscler Suppl. 2008;9:202. Abstract PO48:746

    Article  Google Scholar 

  81. Ridker PM, Danielson E, Fonseca FAH, et al. JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

    Article  PubMed  CAS  Google Scholar 

  82. Ridker PM, Danielson E, Fonseca FAH, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–1182.

    Article  PubMed  CAS  Google Scholar 

  83. Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009 Mar 29. 2009;360:1851–1861.

    CAS  Google Scholar 

  84. Hlatky MA. Expanding the orbit of primary prevention: moving beyond JUPITER. N Engl J Med. 2008;359:2280–2282.

    Article  PubMed  CAS  Google Scholar 

  85. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.

    Google Scholar 

  86. Soran H, Durrington P. Rosuvastatin: efficacy,safety and clinical effectiveness. Expert Opin Pharmacother. 2008;9:2145–2160.

    Article  PubMed  CAS  Google Scholar 

  87. Kostapanos MS, Milionis HJ, Elisaf MS. An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther. 2008;13:157–174.

    Article  PubMed  CAS  Google Scholar 

  88. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;5:415–426.

    Article  Google Scholar 

  89. Levy WC. Observational studies of statins in systolic heart failure. Heart Fail Clin. 2008;4:201–208.

    Article  PubMed  Google Scholar 

  90. Krum H, Latini R, Maggioni AP, et al. Statins and symptomatic chronic systolic heart failure: a posthoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007;119:48–53.

    Article  PubMed  Google Scholar 

  91. Kjeskus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–2261.

    Article  Google Scholar 

  92. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–2442.

    Article  PubMed  CAS  Google Scholar 

  93. GISSI-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:1231–1239.

    Article  PubMed  Google Scholar 

  94. Fornarow G. Statins and n-3 supplementation in heart failure. Lancet. 2008;37:1195–1196.

    Article  Google Scholar 

  95. Selger SR, Weiss NS, Gillen DL, et al. HMG CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297–304.

    Article  Google Scholar 

  96. Wanner C, Krane V, März W, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248.

    Article  PubMed  CAS  Google Scholar 

  97. Fellström B, Zannad F, Schmieder R, et al. AURORA study group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med. 2005;6:9.

    Article  PubMed  Google Scholar 

  98. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–1407.

    Article  PubMed  Google Scholar 

  99. Strippoli GFM, Craig JC. Sunset for statins after AURORA. N Engl J Med. 2009;360:1455–1457.

    Article  PubMed  CAS  Google Scholar 

  100. Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem. 2009;55:219–228.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ANMCO Research Center, Via La Marmora 34, 50121, Florence, Italy

    Gianna Fabbri & Aldo Pietro Maggioni

Authors
  1. Gianna Fabbri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aldo Pietro Maggioni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aldo Pietro Maggioni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fabbri, G., Maggioni, A.P. Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. Adv Therapy 26, 469–487 (2009). https://doi.org/10.1007/s12325-009-0025-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0025-6

Keywords

Search

Navigation